Evidence map›Paper›PMID 25490036›Full record

ArticlePloS one2014

Low VHL mRNA expression is associated with more aggressive tumor features of papillary thyroid carcinoma.

Boban Stanojevic, Vladimir Saenko, Lidija Todorovic, Nina Petrovic, Dragan Nikolic, Vladan Zivaljevic, Ivan Paunovic, Masahiro Nakashima, Shunichi Yamashita, Radan Dzodic

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Effect of Iodine Intake on p14ARF and p16INK4a Expression in Thyroid Papillary Carcinoma in Rats.Medical science monitor : international medical journal of experimental and clinical research · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Boban StanojevicAtomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan; Laboratory for Radiobiology and Molecular Genetics, "Vinca" Institute of Nuclear Sciences, University of Belgrade, Belgrade, Serbia.
Vladimir SaenkoAtomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Lidija TodorovicLaboratory for Radiobiology and Molecular Genetics, "Vinca" Institute of Nuclear Sciences, University of Belgrade, Belgrade, Serbia.
Nina PetrovicLaboratory for Radiobiology and Molecular Genetics, "Vinca" Institute of Nuclear Sciences, University of Belgrade, Belgrade, Serbia.
Dragan NikolicSchool of Medicine, University of Belgrade, Belgrade, Serbia.
Vladan ZivaljevicSchool of Medicine, University of Belgrade, Belgrade, Serbia; Center for Endocrine Surgery, Clinic for Endocrinology, Clinical Center of Serbia, Belgrade, Serbia.
Ivan PaunovicSchool of Medicine, University of Belgrade, Belgrade, Serbia; Center for Endocrine Surgery, Clinic for Endocrinology, Clinical Center of Serbia, Belgrade, Serbia.
Masahiro NakashimaAtomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Shunichi YamashitaAtomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Radan DzodicSchool of Medicine, University of Belgrade, Belgrade, Serbia; Department of Surgical Oncology, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia.
University of Belgrade · RSNagasaki University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alterations of the von Hippel-Lindau (VHL) tumor suppressor gene can cause different hereditary tumors associated with VHL syndrome, but the potential role of the VHL gene in papillary thyroid carcinoma (PTC) has not been characterized. This study set out to investigate the relationship of VHL expression level with clinicopathological features of PTC in an ethnically and geographically homogenous group of 264 patients from Serbia, for the first time. Multivariate logistic regression analysis showed a strong correlation between low level of VHL expression and advanced clinical stage (OR = 5.78, 95% CI 3.17-10.53, P<0.0001), classical papillary morphology of the tumor (OR = 2.92, 95% CI 1.33-6.44, P = 0.008) and multifocality (OR = 1.96, 95% CI 1.06-3.62, P = 0.031). In disease-free survival analysis, low VHL expression had marginal significance (P = 0.0502 by the log-rank test) but did not appear to be an independent predictor of the risk for chance of faster recurrence in a proportion hazards model. No somatic mutations or evidence of VHL downregulation via promoter hypermethylation in PTC were found. The results indicate that the decrease of VHL expression associates with tumor progression but the mechanism of downregulation remains to be elucidated.

Indexed as

AdolescentAdultAgedAged, 80 and overCarcinomaCarcinoma, PapillaryChildDisease-Free SurvivalDNA MethylationDNA Mutational AnalysisFemaleGene Expression Regulation, NeoplasticHumansLogistic ModelsMaleMiddle AgedRNA, MessengerVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID25490036
PMCPMC4260854
OpenAlexW2167229279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.